Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Antibiotics Summit 2019

About Conference


We are happy to invite all the participants from all over the world to attend ‘5th International Conference on Antibiotics’ to be held on March 22-23, 2019 Chicago, USA working under the Theme: The Antibiotic Resistance Crisis: Causes and Threats.

Conference Opportunities:

  • For Professors, Researchers & Faculty Members:

             · Oral Presentation, Poster Presentation, Workshop, Symposium (A group of 3-4 members)

  • For Universities, Associations & Societies:

          · Association Partnering, Collaboration Partnering, Group Participation

  • For Students & Young Research Scholars:

           · Poster Presentations, Young Researcher Forum, Student delegate attendee, Group registrations

  • For Product Manufacturers:

            · Exhibitor & Sponsorships opportunities, Product launch at our event, Conduct Workshop, B2B Networking

  • For Business Delegates:

             · Oral Presentations, Conduct Symposium, Book Launch at our event, Networking opportunities, Audience participation

Conference series LLC Ltd Organizes 3000+ Global Events Every Year across the USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contain over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series LLC Ltd website will provide you list and details about the conferences organize worldwide.

Sessions/Tracks

Track 1: Emerging Antibiotics

The worldwide fundamental antibiotics showcase was esteemed at $39.6 billion of every 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. The worldwide market for antifungal therapeutics was esteemed at $10.7 billion in 2013 and is anticipated to reach $12.2 billion in 2018, a five-year compound yearly development rate (CAGR) of 2.7%. This calls for uniting at a forum to discuss the present scenario, uptake, and consequences associated with antibiotics. This session will witness discussion from global experts on this aspect towards a better efficacy and safe usage of antibiotics.

Track 2: Antibiotics for Emerging and Re-emerging Diseases

This segment manages to bring the most recent medicinal disclosures to the conference. This segment focuses on the targets of acquainting members with real ideas related to the rising and re-rising infectious diseases and building up a comprehension of the connection between biomedical research and personal and public health. New diseases are emerging worldwide and old diseases are re-emerging as infectious operators develop or spread, and as changes occur in the environment, socioeconomic conditions, and populace designs. In like manner, numerous ailments thought to be sufficiently controlled have all the earmarks of being making a rebound. In developed nations, public health measures, for example, sanitation, sewage treatment, inoculation projects, and access to great restorative care-including an extensive variety of antibiotics have virtually eliminated “customary" infections, for example, diphtheria, whooping cough, and tuberculosis. The microbial world is complex, dynamic and constantly emerging. Infectious agents reproduce quickly, mature frequently, cross the particular obstruction between humans and animals, and adjust with relative ease to their new surroundings. On account of these characteristics, infectious agents can modify their epidemiology, their virulence, and their susceptibility to anti-infective medications.

Track 3: Antibiotic Therapy

Fundamental to all good antibiotic (or some other) therapy is the diagnosis. In spite of the fact that antibiotics are, in general, safe, they additionally have numerous dangers related with their utilization, including the advancement of unfavorably susceptible responses, Clostridium difficile infection, and antibiotic resistance, and also a higher sticker price. Accordingly, numerous clinicians incline toward endorsing a shorter treatment course. However, it also is important to give a significant treatment course with the goal that so that an infection is treated adequately and relapse is prevented. This session focuses on the general principles for setting optimal antibiotic durations of therapy.

Track 4: Antimicrobial Resistance: Emergence and its Eccentricity

The developing healthcare issue of antimicrobial resistance essentially affected people in general welfare and has significantly loaded the financial framework on a worldwide scale. With an end goal to battle this rising issue, a few procedures have been executed in the current years to slow down the movement and diminishing the development of antimicrobial resistance. The aim of this conference is to portray the different variables that have added to the present condition of antimicrobial resistance and to assess potential procedures created to decrease the weight of antimicrobial resistance.

The US Centers for Disease Control and Prevention (CDC) reported that anti-toxin safe pathogens sicken 2 million Americans every year and recorded the three most pressing dangers as Clostridium difficile, carbapenem-safe Enterobacteriaceae (CRE), and Neisseria gonorrhea. Anti-toxin safe microorganisms assume a part in 23,000 deaths every year, the CDC reported.

In 2009, the ECDC and The European Medicines Agency (EMA) evaluated that the general cost for the EU in terms of additional human expenses and profitability misfortunes totaled at least EUR 1.5 billion every year. For the US, gauges are as high as $20 billion in abundance coordinate medicinal services costs, with extra expenses to society for lost efficiency as high as $35 billion a year. Studies on deaths infer-able from a little and varying determination of MDR infections demonstrate that every year, these infections result in an expected 25000 deaths in 29 nations in Europe (5.1 for each 100 000 tenants) and 23000 deaths in the US.

Track 5: Current Challenges in Antibiotic Resistance

Antibiotics changed the world. General deals in the present antibiotics and new products advertise were about $40 billion in 2010. It expanded to $41.5 billion in 2013. By 2019, it is anticipated to increase to $67.5 billion, for a 5-year compound annual growth rate (CAGR) of over 9.6%. The biggest section antibiotic drugs showcase was about $38 billion in 2014; this further expanded to $37 billion in 2016, this anticipated to reach $53 billion in 2017, for a 5-year CAGR of 5.9%. Deals in the bacterial vaccines advertise added up to $3.6 billion in 2010 which expanded slightly to $4.5 billion in 2012. This is anticipated to increase to $15 billion of in 2018, for a 5-year CAGR of 31.6%.

Track 6: Drug Discovery and Novel Delivery Systems for Antibiotics

Nowadays, drug delivery organizations are occupied with the advancement of different stage innovations to get a competitive advantage, broaden patent life, and increase market share of their products. Once a compound has demonstrated its incentive in these tests, it will start the procedure of drug development preceding clinical trials

This segment concentrates on current well-tested procedures of determination of compounds from natural and non-natural sources and altering existing classes. In the past, most medications have been found either by distinguishing the key element from conventional cures or by uncertain discovery. Another approach has been to perceive how disease and contamination are controlled at the sub-atomic and physiological level and to target specific substances in light of this data.

Track 7: Microbes in Recent Drug Discovery

Environmental microorganisms are a major source of drug discovery, and several microbial products (antibiotics, anti-tumor items, immunosuppressants and others) are utilized routinely for human treatments. The greater part of these items was acquired from cultivable (<1%) natural organisms, and this implies that the vast majority of microbes were not targeted for drug discovery. With the approach of new and rising innovations, we are ready to gather novel medications from the alleged "uncultivable" microorganisms. In this session, we propose how a multidisciplinary approach consolidating distinctive innovations can facilitate and examine medication disclosure from uncultivable microorganisms and inspect the present limitations of advances and strategies to defeat such confinements that may additionally extend the guarantee of medications from environmental microbes.

Track 8: Antibiotics: Types and Prognosis

The antibiotics market generated sales of US$42 billion in 2009 all-inclusive, representing 46% of sales of anti-infective agents (which additionally incorporate antiviral medications and vaccines) and 5% of the worldwide pharmaceutical market. However, the antibiotics market is maturing; it demonstrated a normal yearly development of 4% in the course of recent years, contrasted and a development of 16.7% and of 16.4% for antiviral medications and vaccines, individually.

The cephalosporin class of antibiotics is the biggest in terms of sells, producing $11.9 billion in 2009, driven by sales the latest generation of medications in this class (cefcapene (Flomax; Shionogi), ceftriaxone (Rocephin; Roche) and cefuroxime (Zinnat; GlaxoSmithKline).

This class represents 28% of the aggregate antibiotic market, and sales demonstrated a development of 3.4% in the course of recent years. With sales of $7.9 billion and 19% of the antibiotic market share in 2010, the second largest medication class is the broad-spectrum penicillin’s, which demonstrated a development of 5% in the vicinity of 2005 and 2012. The third biggest medication class — the fluoroquinolones — had sales of $7.1 billion in 2013, representing 17% of the antibiotic market in 2013. By contrast, as generic versions of an increasing number of macrolides — which had $4.8 billion in sales in 2012 — became available, sales of this class declined by 5% between 2012 and 2014. Overall, the rate of patent expiry of driving antibiotics in the market is set to increase, with a few of the present top selling items confronting patent expiry in the vicinity of 2010 and 2016. These include levofloxacin (Levaquin; Johnson and Johnson), moxifloxacin (Avelox; Bayer/Merck) and linezolid (Zyvox; Pfizer), which are relied upon to lose patent insurance in 2011, 2014 and 2016, respectively.

Track 9:  Advancements in Antibiotic Treatment and Prescribing Protocols

In spite of the fact that the field of antibiotics is growing rapidly as to render it almost kaleidoscopic, amid late months a few points of general intrigue have come into sharp core interest. The subject of first thought will incorporate new medications as well as new types of old medications, and also old medications. Past this, the segment will focus on to two fundamental items, bacterial resistance to antibiotics, and antibiotic toxicity. A variety of biological solutions yet have to be completely investigated.      

Track 10: Antibiotics and Public health

Antibiotics are important in Human Medicine. But there is an increasing prevalence of antimicrobial resistance and that this resistance has clinical implications, therefore a need for mitigation efforts, including awareness on the intake of food and drugs containing antimicrobial agents. Therapeutic anticancer antibiotics have turned into an acknowledged treatment for specific types of cancer. These medications bind particularly to primary and metastatic cancer cells to block cell growth while constraining consequences for encompassing sound cells. Also called antitumor antibiotics, anticancer antibiotics can likewise be utilized to treat or prevent infections expedited by malignancy treatments. Antibiotics are generally recommended amid pregnancy. Antibiotics, for the most part, thought to be safe amid pregnancy: Amoxicillin, Ampicillin, Clindamycin, Erythromycin, Penicillin, Nitrofurantoin. Antibiotics are intended to execute the bacteria that cause infections. Yet, the medications additionally kill off a portion of the ‘good’ bacteria in the gut, which are known to impact absorption and digestion. In this segment, we will explore whether utilization of antibiotics impacts the dangers of treating type 2 diabetes and whether the impact can be ascribed to particular types of antibiotics.

Track 11: Antibiotic Prophylaxis

Antimicrobial prophylaxis is usually utilized by clinicians for the counteractive action of various infectious diseases. Ideal antimicrobial operators for prophylaxis ought to be bactericidal, nontoxic, reasonable, and dynamic against the typical pathogens that can cause surgical site contamination postoperatively. To expand its adequacy, intravenous perioperative prophylaxis ought to be regulated inside 30 to 60 minutes prior to the surgical cut. Antimicrobial prophylaxis ought to be of the brief term to diminish the toxicity and antimicrobial resistance and to decrease the cost. Appropriately directed antibiotic prophylaxis reduces the rate of surgical wound infection. This segment talks about the advantage of taking pre-procedure antibiotics, who should take antibiotics, and gives a clarification of when antibiotics are normally suggested.

Track 12: Antibiotics: Importance in Different Industries

It is assessed that more than one portion of the antibiotics in the U.S. are utilized used in food animal production.  Antibiotics are utilized in food animals to treat clinical illness, to prevent and control common disease events, and to improve animal growth. The utilization of antibiotics in agriculture is routinely portrayed as a noteworthy contributor to the clinical problem of resistant disease in human medicine. The U.S. Food and Drug Administration (FDA) is implementing another system to support more fitting and reasonable utilization of antibiotics in food animal production. The system expects to control antibiotic abuse and overuse by identifying certain antibiotics that will now require veterinary oversight by means of the Veterinary Feed Directive (VFD). The FDA will also help drug companies voluntarily re-label antibiotic products to remove feed efficiency and development advancement claims. Labels will instead emphasize antibiotic use for the prevention, control, and treatment of bacterial infections.

Track 13: Advances in Infectious Antibiotics

The improvement of new antibiotics is urgent to controlling current and future infectious diseases caused by antibiotic-resistant bacteria. Increased advancement costs, the trouble in recognizing new medication classes, unanticipated medication toxicities, the simplicity by which bacteria create imperviousness to new antibiotic agents and the disappointment of numerous operators to address antibiotic resistance particularly. An expected 5– 10% of all hospitalizations are entangled by a nosocomial disease with an expected cost of $4.5– 5.7 billion every year in the USA alone. 15 HAIs likewise have a tendency to have more prominent mortality than CA infections.16 Some antibiotics can be taken orally, while others are managed by infusion or connected topically to the skin.17  Antibiotics are not powerful against infections and ought to never be taken on account of suspected viral contaminations, for example, normal colds. Utilized legitimately, antibiotics can save lives.

Track 14: Antibiotics: Market Analysis & Business Opportunities

The worldwide foundational antibiotics market was esteemed at $39.6 billion in 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. Since 2005 this market apparently grows at a yearly rate of 6.6% until 2011. There are many organizations manufacturing antibiotics nowadays and there are numerous different antibiotics present in the market, for example, aminoglycoside antibiotics and it covers around 79% of the worldwide demand. In addition, alternate antibiotics, for example, penicillin have 8%, tetracycline’s 4%, erythromycin 7%, streptomycin 1% and chloramphenicol has 1 % market.

 

Why to attend?

Antibiotics Summit 2019 is a platform to discuss and learn about the latest advancements in the field of Antibiotics as the world’s consideration turned regarding the urgency of new antibiotics as the antimicrobial resistance is growing day by day. Many developed nations and International health organizations are trying to focus of the current situation and making new policies to prevent the adverse effects of Antibiotic resistance. The two-day event on Antibiotics gathers researchers, academia, labs, drug manufacturers, government agencies, health professionals, hospitals, young investigators, pharma and labs and presents their opinions through key notes, and case study presentations. This conference lays a platform for all the researchers working in the field of Antibiotics to know the latest developments and the current situation of the antibiotic resistance problem.

 

Who Should Attend and Who You’ll Meet

5th International Conference on Antibiotics is exclusively designed for:

  • Researchers
  • Academia
  • Drug Manufacturers
  • Government agencies
  • Healthcare professionals
  • Hospitals/ Clinics
  •  Methodologists
  • Young investigators
  • Medical Directors
  • Principal Investigators
  • Clinical Research organizations
  • Executives of Biotech, Biomedical, Medical devices and Pharmaceutical industries

This conference lays a platform for all the researchers working in the field of microbiology/ antibiotics/ antibiotics resistance to know the latest developments and the current situation of the Antibiotics and combating the Antibiotics Resistance crisis.

Past Conferences

We gratefully appreciate & thank all our wonderful Keynote Speakers, Speakers, Delegates, Students, Organizing Committee Members,  Media Partners for making our Past Antibiotics Summit Conferences (during 2018 in USA Region) the best ever!

   4th International Conference on Antibiotics, R&D, B2B,  April 20-21, 2018

  • Venue: Hilton Garden Inn Las Vegas Strip South 7830 S Las Vegas Blvd, Las Vegas, NV 89123, USA

Keynote Speakers

Past Conferences Keynote Speakers

We thank all our Honourable Keynote Speakers for their valuable support & presence, namely

Chairs/Co-Chairs

Past Conferences Chairs/Co-Chairs

We extend our appreciation towards our Chairs and Co-Chairs of the sessions, namely

  • Hideko Kaji, Thomas Jefferson University, USA
  • Akira Kaji, University of Pennsylvania, USA
  • Tore Midtvedt, Karolinska Institute, Sweden and more…

Market Analysis

The worldwide fundamental antibiotics showcase was esteemed at $39.6 billion of every 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. The worldwide market for antifungal therapeutics was esteemed at $10.7 billion in 2013 and is anticipated to reach $12.2 billion in  2018, a five-year compound yearly development rate (CAGR) of 2.7%. This calls for uniting at a forum to discuss the present scenario, uptake and consequences associated with antibiotics and related areas of research.

 

  • Antibiotic usage varies Globally

 

 

Antibiotics changed the world. General deals in the present antibiotics and new products advertise were about $40 billion in 2010. It expanded to $41.5 billion in 2013. By 2019, it is anticipated to increase to $67.5 billion, for a 5-year compound annual growth rate (CAGR) of over 9.6%. The biggest section antibiotic drugs showcase was about $38 billion in 2014; this further expanded to $37 billion in 2016, this anticipated to reach $53 billion in 2017, for a 5-year CAGR of 5.9%. Deals in the bacterial vaccines advertise added up to $3.6 billion in 2010 which expanded slightly to $4.5 billion in 2012. This is anticipated to increase to $15 billion of in 2018, for a 5-year CAGR of 31.6%.

 

The antibiotics market generated sales of US$42 billion in 2009 all inclusive, representing 46% of sales of anti-infective agents (which additionally incorporate antiviral medications and vaccines) and 5% of the worldwide pharmaceutical market. However, the antibiotics market is maturing; it demonstrated a normal yearly development of 4% in the course of recent years, contrasted and a development of 16.7% and of 16.4% for antiviral medications and vaccines, individually.

 

  • Commonly used antibiotics with their increased percentage of resistance

 

The worldwide foundational antibiotics market was esteemed at $39.6 billion in 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. Since, 2005 this market apparently grows at a yearly rate of 6.6% until 2011. There are many organizations manufacturing antibiotics nowadays and there are numerous different antibiotics present in the market, for example, aminoglycoside antibiotics and it covers around 79% of the worldwide demand. In addition, alternate antibiotics, for example, penicillin have 8%, tetracyclines 4%, erythromycin 7%, streptomycin 1% and chloramnphenicol has 1 % market.

 

  • Antibiotic market

 

Organizations working on Antibiotics around the Globe:

  • Infectious Diseases Society of America
  • World Health Organization
  • U.S. Food and Drug Administration (FDA)
  • Center for a Livable Future (CLF)
  • Centers for Disease Control and Prevention (CDC)
  • American Medical Association
  • Animal Welfare Approved (AWA)
  • Center for Food Safety
  • Center for Science in the Public Interest (CSPI)
  • Food Animal Concern Trust (FACT)
  • The Humane Society of the United States (HSUS)
  • The Pew Charitable Trusts
  • Food and Water Watch
  • Healthy Food Action
  • Keep Antibiotics Working (KAW)
  • Natural Resources Defense Council (NRDC)
  • American Nurses Association
  • American Public Health Association
  • Institute of Medicine, National Academies of Science
  • American Society for Microbiology  

Moderators

Past Conferences Moderators

Conference series LLC Ltd expresses its gratitude to the conferences Moderators, for taking up the responsibility to coordinate during the sessions, we are indebted to your support, namely

  • Nataliya Roth, University of Natural Resources and Life Sciences, Austria
  • Helieh S Oz, UK Medical Center, USA and more…

Past Conference Report

Antibiotics Summit 2018

Conference Series LLC Ltd hosted the “4th International Conference on Antibiotics R&D, B2B (Antibiotics Summit 2018) during April 20-21, 2018, 2017 at Hilton Garden Inn Las Vegas Strip South 7830 S Las Vegas Blvd, Las Vegas, NV 89123, USA.

Antibiotics Summit 2018 is specifically premeditated with a unifying axiom providing platform to widen the imminent scientific discoveries in the field of Antibiotics and Antibiotic Resistance and to deliver novel ideas besides incorporating better understanding of their role in Pharma, Drug Manufacturers, Business Management and Marketing. The scientific meeting has laid the path for the development and the validation of Antibiotics and Antibiotic Resistance under the theme of Antibiotics Research: Current challenges and perspectives”.

The conference invited Scientific Professionals, Researchers and Corporate Leaders from diverse disciplines emphasizing the areas of types & approaches for Antibiotic Treatment, The Emergence of Antimicrobial Resistance, Antibiotic Resistance: Opportunities and Challenges, Antibiotics for Emerging and Re-emerging Diseases, Antibiotic Prophylaxis etc.

Conference Series LLC Ltd is prerogative to thank the Organizing Committee, Editorial Board Members and Moderator – Dr. Nataliya Roth, University of Natural Resources and Life Sciences, Austria, speaker participants, poster presenters and attendees for enormous support and participation in this grand venture.

The highlights of the meeting were the eponymous lectures, delivered by the following speakers:

Akira Kaji, University of Pennsylvania, USA

Rongshi Li, University of Nebraska Medical Center, USA

John J S Cadwell, FiberCell Systems Inc., USA

Hideko Kaji, Thomas Jefferson University, USA

Helieh S. Oz, American Association of Gastroenterology, USA

Tore Midtvedt, Karolinska Institute, Sweden

Nataliya Roth, University of Natural Resources and Life Sciences, Austria

By the endless support of the Journal of Antivirals & Antiretrovirals & Journal of Medical Toxicology Research & Archives of Medical Biotechnology. Conference Series LLC Ltd is pleased to announce our 5th International Conference on Antibiotics March 22-23, 2019 at Chicago, USA


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date March 22-23, 2019

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Day 1

Past Conference Report

Supported By

Journal of Antivirals & Antiretrovirals

Journal of Pharmacovigilance

Journal of Bioequivalence & Bioavailability

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by